Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • minnesotafarmcountry minnesotafarmcountry Nov 27, 2012 1:05 PM Flag

    Well, Adam Fuerstein/The Street is very bullish ...

    The patient will accumulate for longer term!

    1. Sarepta Therapeutics(SRPT_) +593%

    How fitting that Sarepta is the best performing biopharma stock of 2012 given the company's lead drug eteplirsen shows tremendous promise as a groundbreaking treatment for Duchenne muscular dystrophy (DMD), a rare genetic disorder that forces patients into wheelchairs in their teens and can be fatal shortly after.

    Initial results in April from a phase II study of eteplirsen in DMD patients were tantalizing but essentially ignored by Wall Street. Follow-up data from the same study announced in July and presented in October were nothing short of astonishing. The eteplirsen data are so good that Sarepta is hoping to convince the FDA to approve the drug early. DMD advocates are already mobilizing to lobby FDA on the company's behalf.

    Sarepta will be meeting with FDA officials early next year to plot a course for eteplirsen's approval. If FDA agrees to review eteplirsen based on the small phase II study and the drug is ultimately approved next year, Sarepta could very easily find itself topping the Top 10 list in 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SRPT
32.00-0.63(-1.93%)Jul 27 4:00 PMEDT